Category Archives: Advisory Committee Prepapartion

The Evolving Nature of AdComm Watching – Not for the Birds

Some people watch birds.  They get field glasses, walk in groups in wooded areas, and observe, catalog, and discuss birds.  There are volumes of books written about various aspects of bird watching.  Different shapes, different sizes, different species.  I’ve noticed, … Continue reading

Posted in Advisory Committee Prepapartion | Comments Off

Vacancies on FDA Advisory Committees

Anyone attending an FDA Advisory Committee meeting will likely discern right away that the job of serving in the capacity as a member is probably not terribly exciting.  You have to travel from where you live, review mountains of data, … Continue reading

Posted in Advisory Committee Prepapartion | 1 Comment

FDA Advisory Committee Action for 2012

As 2011 ended, there was a great deal of looking back at events of the year.  As it affected new medical products, FierceBiotech reported on Friday that drug approvals during the year increased to 30 last year. Now as we … Continue reading

Posted in Advisory Committee Prepapartion | 2 Comments

FDA Making Transparency Increasingly Clear

This week a number of people took note when the FDA announced the issuance of a report that outlined eight new proposals to increase transparency by allowing greater access to the agency’s compliance and enforcement data.  The eight proposals are … Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Comments Off

AdComm Vacancies and Conflict of Interest Standards

Last week at the Reuter’s Health Summit held in New York, Janet Woodcock, the head of the Center for Drug Evaluation and Research was quoted as saying that she expected drug approvals to increase this year, but that the financial … Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Comments Off